Marcelo Correia, MD
Endocrinology, Diabetes & Metabolism · Iowa City, IANPI 1235421140
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,138 of the $9,568 with a category attached, or 74.6%. Novo Nordisk accounts for 78.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $4,740, more than ten times the $56 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $341.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$7K
- Novartis$2K
- Boston Scientific$149
- Ionis Pharmaceuticals, Inc.$90
- Abbott$68
- Medtronic$60
- plus $19 from 1 others
Across 350 payments — averaging $4417.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$749K
- Eli Lilly$506K
- Novo Nordisk AS$286K
- Pfizer$5K
What the payments were for
- Consulting fees$7,13875%
- Travel & lodging$1,03511%
- Food & beverage$1,17012%
- Education$2262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $7,471 |
| Novartis | 7 | $1,711 |
| Boston Scientific | 2 | $149 |
| Ionis Pharmaceuticals, Inc. | 1 | $90 |
| Abbott | 1 | $68 |
| Medtronic | 1 | $60 |
| Dexcom, Inc. | 1 | $19 |
How this compares
$9,568 in reported general payments places this provider in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 106 | $69,976 |
| MounjaroTirzepatide | 58 | $57,679 |
| OzempicSemaglutide | 41 | $52,887 |
| Praluent PenAlirocumab | 29 | $19,254 |
| JardianceEmpagliflozin | 17 | $10,442 |
| JanuviaSitagliptin Phosphate | 12 | $6,081 |
| Hydrocortisone | 38 | $1,306 |
| FenofibrateFenofibrate,micronized | 13 | $549 |
| Topiramate | 79 | $536 |
| Rosuvastatin Calcium | 27 | $445 |
| Levothyroxine Sodium | 45 | $341 |
| Alendronate Sodium | 19 | $223 |
| Atorvastatin Calcium | 12 | $62 |
| Glipizide | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $7,471 | $52,88741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Iowa City
- Ayotunde DokunIowa City$31K
- Thomas OdorisioIowa City$7K
- Amie OgunsakinIowa City$2K
- Joseph DillonIowa City$2K
- Adeyinka TaiwoIowa City$923
- Rana TaljIowa City$566
- Kathleen RobinsonIowa City$298
- Helen Prathiba GnanapragasamIowa City$281
- Brian OneillIowa City$164
- Amr WahbaIowa City$164
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.